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doi:10.1016/j.jtcvs.2005.10.027bjective: Because venous thromboembolism results in important postoperative
orbidity and mortality after pneumonectomy for malignancy, we sought to deter-
ine its prevalence, location, management, timing, and risk factors. We also
valuated short- and long-term outcomes of patients in whom venous thromboem-
olism developed compared with those of patients in whom it did not.
ethods: Between January 1990 and January 2001, 336 patients underwent pneu-
onectomy for malignancy. Patients were considered to have venous thromboem-
olism if they were identified as having deep vein thrombosis or pulmonary embolus
hrough chart review, including pulmonary imaging studies. All patients were
anaged with anticoagulation or anticoagulation plus thrombolysis.
esults: Twenty-five (7.4%) patients had postoperative venous thromboembolism,
ith peak incidence 7 days after the operation; most had already been discharged
rom the hospital. Higher pack-years of smoking was associated with increased risk,
s well as with earlier occurrence of venous thromboembolism (P  .04). Survival
as 55% at 6 months and 13% at 18 months; mode of death was cancer in 14 (61%)
f 23, respiratory failure in 4 (17%) of 23, multisystem organ failure in 3 (13%) of
3, myocardial infarction in 1 (4.4%) of 23, and uncertain in 1 (4.4%) of 23. Low
reoperative forced vital capacity was predictive of poor long-term survival (P 
02). Patients with venous thromboembolism had substantially lower survival than
redicted from competing-risks analysis of survival without venous thromboembo-
ism (13% vs 60% at 18 months), and this difference persisted after censoring for
eaths directly attributable to venous thromboembolism.
onclusions: Venous thromboembolism is surprisingly common after pneumonec-
omy for malignancy and portends poor survival. Improved screening and better
rophylaxis might prevent this complication and enhance outcome.
eep vein thrombosis complicates the postoperative course of patients un-
dergoing surgical intervention for cancer more often than that of patients
undergoing surgical intervention for benign disease.1 This is particularly
rue for patients with lung cancer, whose risk of venous thromboembolism (VTE) is
0 times greater than that of the general population, with an incidence of 44.4 per
000 person-years.2 Patients who undergo thoracotomy and pulmonary resection for
ancer are at high risk for VTE, perhaps because in addition to the thromboembolic
isk of a major operation, they manifest a hypercoaguable state caused by their
nderlying malignancy. Because of compromised pulmonary reserve, patients un-
ergoing pneumonectomy have the most at stake from thromboembolism and
epresent the highest surgical risk.
Therefore, we sought to determine the prevalence, location, management, timing,
nd risk factors for VTE after pneumonectomy for cancer. We also evaluated short-
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 3 711
ao
P
P
F
p
D
h
a
P
P
5
d
t
p
e
p
i
D
s
s
b
c
r
o
i
v
m
C
c
i
L
p
d
p
p
d
t
O
P
t
S
p
m
a
T
T
t
a
o
m
r
d
d
d
a
o
s
f
b
r
o
a
s
a
w
c
d
e
e
t
t
h
C
T
r
o
(
V
e
h
a
R
P
P
h
e
c
w
b
i
v
h
w
b
c
General Thoracic Surgery Mason et al
7
G
TSnd long-term outcomes of patients in whom VTE devel-
ped compared with those of patients in whom it did not.
atients and Methods
atients
rom January 1990 through January 2001, 336 patients underwent
neumonectomy for cancer at The Cleveland Clinic Foundation.
ata were extracted from the Thoracic Surgery Registry, which
as been approved for research by the institutional review board,
nd supplemented by detailed review of all medical records.
rophylaxis and Diagnosis of VTE
ostoperative prophylaxis for VTE was subcutaneous heparin,
000 units twice daily, and pneumatic stockings through hospital
ischarge. All patients were ambulated immediately postopera-
ively, as well as after VTE, unless cardiorespiratory compromise
rohibited it.
Clinical signs of VTE were observed on history and physical
xamination and included upper or lower extremity swelling, calf
ain, and shortness of breath. Clinical findings were confirmed by
maging for deep vein thrombosis, pulmonary embolism, or both.
eep vein thrombosis was confirmed by means of Doppler ultra-
onography; occasionally, venography was performed for diagno-
is and therapy. No preoperative screening for deep vein throm-
osis was performed, and all vases of VTE were diagnosed from
linical suspicion. Patients were instructed to call after discharge to
eport symptoms of upper or lower extremity swelling, calf pain,
r shortness of breath and then were readmitted.
Deep vein thrombosis of the upper extremity was defined as
nvolving the basilic, axillary, brachiocephalic, and internal jugular
eins. Lower extremity deep vein thrombosis included the com-
on femoral, superficial femoral, popliteal, tibial, and soleal veins.
entral venous thrombosis included the superior or inferior vena
ava, as well as the iliac veins. Standard criteria for noncompress-
ble echogenic filling defects defined by our Vascular Medicine
aboratory were used to identify deep vein thrombosis. Venogra-
hy was not required for confirmation. Pulmonary embolus was
iagnosed on the basis of a mismatched defect on ventilation-
erfusion scanning coupled with clinical suspicion. Ventilation-
erfusion scans and pulmonary angiograms were largely aban-
oned with the advent of pulmonary embolism protocol computed
omography.
utcomes
rimary outcome was all-cause mortality. Vital status was ob-
ained by means of systematic follow-up augmented by the Social
ecurity Death Index.3,4 Median follow-up was 1.6 years, with 828
atient-years available for analysis. When possible, we obtained
ode of death from follow-up contact with families and autopsy
Abbreviations and Acronyms
VTE venous thromboembolismnd chart review. c
12 The Journal of Thoracic and Cardiovascular Surgery ● Marciming of VTE and its Risk Factors
iming of VTE was determined from the date of the operation to
he date of diagnosis. Interval from VTE to hospital discharge was
lso recorded. Estimates of freedom from occurrence of VTE were
btained by using the Kaplan-Meier method and by using a para-
etric method that resolves the number of phases of instantaneous
isk and estimates shaping parameters.5 This method allowed us to
etermine the time of peak identification of VTE, as well as risk of
eath.
Risk factors for VTE were identified in the hazard function
omain (see Appendix 1 for list of variables included in the
nalysis).5 Continuous and ordinal variables were retained in their
riginal state to maximize information content, with original mea-
urement scales calibrated to assumptions of the analysis by trans-
ormation as necessary (linearization). Variable selection used
ootstrap aggregation (bagging), with automated analyses of 1000
andom data sets performed by using a variable retention criterion
f a P value of less than .1.6,7 Resulting models were aggregated,
nd results wee expressed as the frequency of occurrence of both
ingle factors and closely related clusters of factors. We included
ny factor appearing in at least 50% of the analyses. In addition,
e included the most frequently occurring representative for any
luster appearing in at least 50% of the analyses.
Coefficients in multivariable models are presented with 1 stan-
ard error of the estimates, and freedom from events and hazard
stimates are accompanied by asymmetric 68% confidence limits
quivalent to 1 standard error. Hazard ratios were not used because
he model does not assume proportional hazards and because
ransformations were made of continuous variables that made
azard ratios uninterpretable.
omparison of Outcome
o determine the effect of VTE on outcome, we used competing-
isks analysis to compare survival of patients before VTE devel-
ped with that after VTE was diagnosed.8 Competing events were
1) death before VTE and (2) VTE. Risk factors for death before
TE were identified as described above. Then for each patient
xperiencing VTE, a survival curve was predicted as if he or she
ad not experienced VTE (expected survival). These curves were
ggregated and compared with observed survival.9
esults
revalence, Location, and Management of VTE
revalence of VTE was 7.4% (25/336); 17 (68%) patients
ad deep vein thrombosis only, 5 (20%) had pulmonary
mbolism only, and 3 (12%) had both. The 20 cases of
onfirmed deep vein thrombosis occurred in 33 locations,
ith some patients having more than one focus of throm-
osis. These included 14 upper extremity, 15 lower extrem-
ty, and 4 central (iliac and vena cava) cases.
All patients were immediately anticoagulated with intra-
enous heparin and later converted to warfarin; 2 with
emodynamic instability and pulmonary embolism under-
ent thrombolysis. Of the 8 patients with pulmonary em-
olism admitted to the intensive care unit for respiratory
ompromise, 7 required intubation, and 1 had inferior vena
ava filter placement. One patient with deep vein thrombo-
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G
TSis alone had inferior vena cava filter placement. No patient
ith VTE had heparin-induced thrombocytopenia, and no
atient had major bleeding requiring reoperation after
nticoagulation.
Six patients were given diagnoses of VTE preoperatively; 4
f these had deep vein thrombosis and were treated perio-
eratively with standard prophylaxis, including subcutane-
us heparin. One patient with preoperative deep vein throm-
osis had an acute deep vein thrombosis postoperatively.
wo patients had pulmonary embolism preoperatively; 1
as treated with intravenous heparin perioperatively and the
ther with an inferior vena cava filter. Neither experienced
ostoperative pulmonary embolism.
iming of VTE and Its Risk Factors
he incidence of VTE peaked 7 days after the operation,
nd most patients (64%) who had diagnoses of VTE had
lready been discharged; only 9 (36%) had it while still in
he hospital (Figure 1). Postoperative length of stay of
atients undergoing pneumonectomy decreased during this
tudy, from approximately 14 days in 1990 to 7 days in
000. This trend made it increasingly likely that patients
ould have VTE at home and require readmission. The
ncidence of VTE after the first 2 postoperative weeks
ecreased rapidly, and few events occurred after the first
onth (Figure 2).
Higher pack-years of smoking was identified as a preop-
rative risk factor for VTE (Table 1). The more pack-years
atients smoked, the higher their likelihood of having VTE
Figure 3).
eath After VTE and Its Risk Factors
urvival after VTE diagnosis was 55%, 34%, and 13% at 6,
igure 1. Timing of venous thromboembolism (VTE) relative to
ime of hospital discharge after pneumonectomy.2, and 18 months, respectively. We attempted to determine t
The Journal of Thoracichether patients with pulmonary embolism had worse sur-
ival than those with deep vein thrombosis and found no
ifference (P  .7). Furthermore, we found no difference in
utcomes in patients with upper versus lower limb deep
ein thrombosis. Pulmonary embolism occurred more often
n patients with lower extremity (2/9) than upper extremity
eep vein thrombosis (1/8), but the difference was not
tatistically significant.
The only risk factor for death after VTE was lower
orced vital capacity expressed as a percentage of normal
alue (P  .02). This was particularly true for patients with
forced vital capacity of less than 80%, who experienced a
teep decrease in 1-year survival (Figure 4).
Mode of death was cancer in 14 (61%), respiratory failure
n 4 (17%), multisystem organ failure in 3 (13%), myocardial
nfarction in 1 (4.4%), and uncertain in 1 (4.4%).
omparison of Outcome
as mortality higher than expected in patients with VTE?
xpected survival was calculated on the basis of the com-
eting risk of death before VTE. Risk factors for death
ncluded male sex, preoperative radiotherapy, lower forced
xpiratory volume in 1 second (percentage of normal value),
igher pT, and increased pack-years of smoking (Table 2).
xpected survival was considerably higher than observed
urvival (60% vs 13% at 18 months; Figure 5). This differ-
nce persisted after censoring 3 deaths directly attributable
igure 2. Freedom from venous thromboembolism (VTE) after
neumonectomy. Each circle represents an event, vertical bars
re 68% confidence limits equivalent to 1 standard error, and
umbers in parentheses are numbers of patients remaining at
isk. The solid line enclosed within dashed 68% confidence limits
s the parametric estimate that generated the hazard function
hown in Figure 1.o VTE (60% vs 15%).
and Cardiovascular Surgery ● Volume 131, Number 3 713
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TSABLE 1. Preoperative patient and tumor characteristics
haracteristic Overall (n  336), no. (%)
Venous thromboembolism
P valueYes (n  25), no. (%) No (n  311), no. (%)
atient
Male sex 248 (74) 19 (76) 229 (74) .8
Age (y)* 61 11 61 13 61  11 .9
BMI (kg · m2)* 26  5 26 5 26  5 .7
Pulmonary function tests
FEV1*
Liters 2.4 0.65 2.3 0.45 2.4  0.66 .5
% of normal value 73 18 72 12 72  19 .8
FVC*
Liters 3.5 0.87 3.3 0.74 3.5  0.90 .4
% of normal value 85 17 82 13 84  20 .5
FVC/FEV1 0.69 0.11 0.71 0.11 0.68 0.12 .3
Smoker (pack-years)† 24, 45, 80 30, 50, 100 22, 45, 80 .02
Comorbidity
Insulin-treated diabetes‡ 7 (2) 0 (0) 7 (2) 1.0
Non–insulin-treated diabetes 25 (7) 2 (8) 23 (7) 1.0
History of hypertension 113 (34) 7 (28) 106 (34) .5
Coronary artery disease§ 63 (19) 4 (16) 59 (19) 1.0
History of AF‡ 18 (5) 1 (4) 17 (6) 1.0
History of DVT 4 (1) 1 (4) 3 (1) .3
History of PE 2 (0.6) 0 (0) 2 (0.6) 1.0
History of CVA 16 (5) 0 (0) 16 (5) .6
rimary lung cancer
Histology .8
Squamous cell 119 (36) 11 (52) 108 (35)
Adenocarcinoma 186 (56) 9 (43) 177 (57)
Mixed type 2 (0.6) 0 (0) 2 (0.6)
Mesothelioma 14 (4) 1 (5) 13 (4)
Small cell 2 (0.6) 0 (0) 2 (0.6)
Metastatic 7 (12) 0 (0) 7 (2)
Renal 1 (0.6) 0 (0) 1 (0.3)
Unknown 1 (0.3) 0 (0) 1 (0.3)
pT classification¶ .3
1 51 (16) 1 (5) 50 (17)
2 168 (54) 14 (74) 154 (52)
3 57 (18) 3 (16) 54 (18)
4 37 (12) 1 (5) 36 (12)
pN classification¶ .9
0 100 (32) 6 (32) 94 (32)
1 96 (31) 6 (32) 90 (31)
2 107 (34) 6 (32) 101 (34)
3 10 (3) 1 (5) 9 (3)
pM classification¶ 1.0
0 303 (97) 19 (100) 284 (97)
1 10 (3) 0 (0) 10 (3)
Stage# .6
IA 21 (7) 0 (0) 21 (7)
IB 52 (17) 4 (21) 48 (16)
IIA 11 (4) 0 (0) 11 (4)
IIB 72 (23) 7 (37) 65 (22)
IIIA 105 (34) 6 (32) 99 (34)
IIIB 41 (13) 2 (10) 39 (13)
IV 10 (3) 0 (0) 10 (3)
14 The Journal of Thoracic and Cardiovascular Surgery ● March 2006
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TSiscussion
atients with thoracic malignancies undergoing surgical
ung resection are at particular risk for morbidity or mor-
ality from VTE. Typically, they are smokers with some
omponent of chronic obstructive pulmonary disease. Pul-
onary embolism has been found to be an important cause
f acute fatality after lung resection, with 1.85% of patients
n one study dying of acute cardiorespiratory failure, the
ajority because of pulmonary embolus.10
Surgical resection reduces respiratory reserve and the
bility to tolerate VTE. Patients undergoing pneumonec-
omy represent the highest risk category because their re-
piratory reserve is most compromised, and their increased
ulmonary artery pressures and decreased pulmonary vas-
ular bed leave little margin to tolerate VTE.
rincipal Findings
Prevalence, location, and management of VTE. We
ound no difference in outcome between patients with deep
ein thrombosis and those with pulmonary embolism. Up-
ABLE 1. Continued
haracteristic Overall (n  336), no. (%)
Preoperative therapy**
Chemotherapy 68 (21)
Radiotherapy 69 (21)
Chemoradiotherapy 57 (17)
MI, Body mass index; FEV1, forced expiratory volume in 1 second; F
E, pulmonary embolism;CVA, cerebrovascular accident. *Mean standar
One missing in “No” group. Four missing in “Yes” group. ¶Six missing in
8 missing in “No” group. **Not mutually exclusive; 4 missing in “Yes” g
igure 3. Freedom from venous thromboembolism (VTE) at 30 days
fter pneumonectomy for cancer according to pack-years of
moking (univariable analysis). The solid line is the point esti-
ate enclosed within dashed 68% confidence limits. o
The Journal of Thoracicer extremity deep vein thromboses were surprisingly com-
on, most likely related to central line placement. We
outinely place central lines in all patients undergoing pneu-
onectomy, and all patients with upper extremity deep vein
hrombosis in our study had central lines. This is consistent
ith studies showing that symptomatic catheter-related
hrombosis occurs in 4% to 14% of patients with a central
ine, with the highest incidence in patients with cancer.11
hemotherapeutic infusion or mediastinal radiation might
dd to the venous injury, contributing to deep vein throm-
osis.12-14 Although there is a perception that deep vein
hrombosis is less worrisome when it occurs in the upper
xtremities, we found that this complication clearly carries
isk: 1 of 8 patients with upper extremity deep vein throm-
osis also had pulmonary embolism, and long-term survival
as decreased. We presently make an effort to minimize
entral line use and remove catheters early after surgical
ntervention.
Managing VTE after pneumonectomy is challenging.
ortality is high, particularly in the setting of pulmonary
mbolism, suggesting that management practices can be
Venous thromboembolism
P valueYes (n  25), no. (%) No (n  311), no. (%)
4 (19) 64 (21) 1.0
5 (24) 64 (21) .8
4 (19) 53 (17) .8
orced vital capacity; AF, atrial fibrillation; DVT, deep vein thrombosis;
iation. †Fifteenth, 50th, and 85th percentiles. ‡Three missing in “No” group.
” group, and 17 missing in “No” group. #Six missing in “Yes” group, and
and 6 missing in “No” group.
igure 4. One-year survival after venous thromboembolism ac-
ording to forced vital capacity (FVC) expressed as a percentageVC, f
d dev
“Yesf normal value (univariable analysis). Depiction is as in Figure 3.
and Cardiovascular Surgery ● Volume 131, Number 3 715
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TSmproved. We instituted therapeutic intravenous anticoagu-
ation with heparin in all patients but proceeded to throm-
olysis in only 1 patient, who survived. We are reluctant to
nstitute thrombolysis early postoperatively because it could
ead to bleeding into the pneumonectomy space, although
e did not have this complication. Given the overall high
ortality, proceeding to thrombolysis earlier might be war-
anted. This has been shown to result in greater and faster
mprovement in angiographic and hemodynamic parameters
hen compared with heparin alone in patients with pulmo-
ary embolism.15 Catheter-based or operative thrombec-
omy might also be considered as an early intervention.
Inferior vena cava filters were successfully used in 1
atient with pulmonary embolism preoperatively, as well as
n 1 patient who had postoperative deep vein thrombosis.
lthough the majority of our patients with VTE had deep
ein thrombosis alone, a substantial proportion had pulmo-
ary embolism with important mortality. For this reason, we
trongly consider inferior cava filter placement in all pa-
ients with VTE undergoing pneumonectomy, particularly
hose with proximal lower extremity deep vein thrombosis.
Timing of VTE and its risk factors. The fact that 7.4%
f our patients had VTE postoperatively and more than half
f these had it after being discharged suggests that our
rophylaxis regimen needs to be improved and possibly
engthened. All patients received pneumatic compression
tockings and 5000 units of unfractionated heparin twice a
ay. Nevertheless, the prevalence of deep vein thrombosis
nd pulmonary embolism was high, although lower than in
he postthoracotomy patients studied by Ziomek and col-
eagues,16 who detected postoperative thromboembolism in
9% of patients. Our results were comparable with those of
large series of patients who underwent pneumonectomy
ABLE 2. Incremental risk factors for death before venous
hromboembolism
isk factor Coefficient  SE P value
arly hazard phase
None
ate hazard phase
Male sex 0.43 0.17 .01
Lower FEV1 (% of normal value)* 0.98 0.44 .03
History of smoking 1.1 0.79 .10
Pack-years† 5.9  2.2 .007
Pack-years‡ 1.1  0.45 .02
Higher pT stage§ 0.37 0.17 .03
Preoperative radiotherapy 0.36 0.17 .03
E, Standard error; FEV1, forced expiratory volume in 1 second. *(1/FEV1)
2,
nverse squared transformation. †(50/smoking pack-years  1), inverse
ransformation. ‡Ln(smoking pack-years  1), logarithmic transformation.
Ln(pT stage), logarithmic classification.or malignant mesothelioma. In that study deep vein throm- s
16 The Journal of Thoracic and Cardiovascular Surgery ● Marcosis occurred in 6.4% of patients postoperatively, and
ulmonary embolism occurred in 1.5%.17
Early hospital discharge after surgical intervention might
e shifting occurrence of VTE to the outpatient setting,
eading to underestimation of risk.18 We are considering
hether another form of prophylaxis should be used, such
s low-molecular-weight heparin or routine addition of war-
arin, as recommended for other high-risk patient popula-
ions.19,20 Low-molecular-weight heparin (enoxaparin) has
een used as prophylaxis for a month after oncologic sur-
ery, with reduction in VTE.21 Our results suggest that a
imilar regimen for patients undergoing pneumonectomy
ight be warranted. Prophylaxis to 1 month seems to be an
ppropriate interval because the majority of VTE cases are
lustered in this period.
The only risk factor we identified for VTE after pneu-
onectomy was increased pack-years of smoking. Smoking
ncreases cardiovascular and cancer risk, but the reason for
ts association with VTE is unclear, except in its combined
se with oral contraceptives.22
Death after VTE and its risk factors. Patients who
ndergo pneumonectomy for malignancy are at high risk of
TE despite prophylaxis and of dying directly from VTE or
ther causes. We found that mortality of patients with VTE
as high, both in those who had pulmonary embolism and
n those who had deep vein thrombosis alone.
We found pulmonary embolism after pneumonectomy to
e poorly tolerated. Pneumonectomy alone causes increased
ight ventricular afterload; 50% of patients given diagnoses
f pulmonary embolism have echocardiographic findings of
ight ventricular dysfunction and increased pulmonary pres-
igure 5. Expected upper solid curve enclosed in 68% confidence
evels versus observed (circles) survival after diagnosis of ve-
ous thromboembolism. Actuarial and parametric depiction of the
atter is as in Figure 2.F
l
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tures.23,24 The added strain pulmonary embolism places on
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G
TSright ventricle already attempting to compensate for in-
reased afterload might explain the high mortality we ob-
erved. This theory is supported by the fact that the only risk
actor for death after VTE that we identified was reduced
ulmonary function.
Comparison of outcome. Patients with VTE had sub-
tantially worse outcomes than expected. Studies of VTE in
atients with cancer have shown that they have a 4- to
-fold higher risk of dying than if this complication had not
ccurred.2,25-27 This was attributed both to the mortality
ssociated with VTE and to its being a marker of more
ggressive malignancies, and it was true for patients with
ocoregional, as well as metastatic, disease. Patients with a
igher disease burden might be more likely to have VTE.28
n fact, patients who undergo pneumonectomy tend to have
ore central and larger tumors. Our study shows that VTE
s an independent marker for decreased survival for thoracic
alignancies.
imitations
he main limitation of our study is that although we have
dentified risk factors for VTE (eg, smoking) and shown that
oor pulmonary function is a marker of poor outcome, these
re not modifiable when patients present for surgical inter-
ention. Furthermore, although it is intuitive that pulmonary
mbolism portends decreased survival, it is unclear how
eep vein thrombosis alone contributes to higher mortality;
athophysiology of this remains to be explained.
We have likely underestimated the true prevalence of
TE because we obtained imaging studies only on patients
ith clinical signs of VTE. In addition, we did not perform
reoperative screening for deep vein thrombosis or pulmo-
ary embolism, although 6 patients in our series were given
reoperative diagnoses of VTE, 4 with deep vein thrombo-
is and 2 with pulmonary embolism. It is well known that
atient history and physical examination are of limited
alue in diagnosing deep vein thrombosis.29 Screening for
TE is an important consideration, although routine sur-
eillance with noninvasive tests has low sensitivity and
pecificity.30 The lack of preoperative and postoperative
creening for VTE in our study might have caused us to
nderestimate its prevalence and overestimate its medical
onsequences. Asymptomatic patients with VTE might
ave had benign clinical courses. Finally, this study does
ot explain whether VTE after pneumonectomy is a direct
ause of poor outcome or only a marker of it.
onclusions
ur study has shown that VTE is a common event after
neumonectomy and that current prevention and treatment
fforts are inadequate. Preoperative and postoperative screen-
ng for VTE might be warranted in this high-risk population.
reoperative screening might include duplex scanning, as well
1
The Journal of Thoracics screening hemostatic factors for hypercoagulable state.
ostoperative screening would be duplex scanning on post-
perative day 7 before discharge. Although this study fo-
used specifically on patients undergoing pneumonectomy,
he conclusions are likely applicable to all patients under-
oing thoracotomy for malignancy because of the similar
isk factors, surgical procedure, and perioperative course.
uture studies should also be directed at decreasing the
ccurrence of VTE through an improved prophylaxis regi-
en and then evaluating whether this enhances outcome.
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ppendix 1. Variables used in analyses
emography
ex, age at the time of the operation (years), height (centimeters),
eight (kilograms)
ancer variables
athologic T stage, tumor size, radiation therapy, chemotherapy
ulmonary function
orced expiratory volume in 1 second, forced expiratory volume in
second (percentage of normal value), forced vital capacity,
orced vital capacity (percentage of normal value)
ardiac comorbidity
oronary artery disease, atrial fibrillation, cerebrovascular accident,
eart failure
oncardiac comorbidity
istory of diabetes, history of smoking, history of hypertension
xperience
ate of operation
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